Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol

Conclusion: Analysis of postlaunch data confirmed ERC ’s effectiveness in increasing serum 25D and reducing PTH levels without statistically significant or notable impact on serum Ca and P levels. A significant percentage of these subjects achieved 25D levels ≥30 mg/mL and PTH levels which decreased by at least 30% from baseline. Dose titration to 60 mcgs was rarely prescribed. Closer patient monitoring and appropriate dose titration may have led to a higher percentage of subjects achieving an increase in 25D levels to at least 50 ng/mL and a reduction in PTH levels of at least 30%.Am J Nephrol
Source: American Journal of Nephrology - Category: Neurology Source Type: research